Autolus Therapeutics (NASDAQ:AUTL) Posts Earnings Results

Autolus Therapeutics (NASDAQ:AUTL) issued its earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10), Zacks reports. During the same period in the prior year, the firm posted ($0.26) earnings per share.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL traded down $0.01 during mid-day trading on Wednesday, hitting $3.32. 912,652 shares of the company were exchanged, compared to its average volume of 1,427,314. The firm has a market cap of $883.42 million, a price-to-earnings ratio of -2.77 and a beta of 2.04. Autolus Therapeutics has a 1-year low of $3.06 and a 1-year high of $7.45. The stock has a 50 day simple moving average of $3.97 and a 200-day simple moving average of $4.00. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.